Drugs / ConvitVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06023277 | Apr 2024 → Mar 2025 overdue | breast cancer | Jacinto Convit World Organization Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ConvitVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06023277 ↗ |
| Modality | Vaccine | “ConvitVax is a vaccine made of three components” NCT06023277 ↗ |